What Is Exomind?

Key Takeaways

EXOMIND is BTL's device/system for delivering repetitive transcranial magnetic stimulation. ExoTMS is BTL's proprietary implementation of TMS. The underlying principle remains electromagnetic induction: a coil produces rapidly changing magnetic fields that induce electrical currents in the brain.[1][2][3]

The useful distinction is simple. TMS is the broader treatment technology; ExoTMS is BTL's particular technology and delivery system. That means evidence about TMS cannot automatically be treated as evidence for every EXOMIND claim.

For patients in Malaysia, EXOMIND appears in the Malaysian Medical Device Register under BTL Industries Malaysia Sdn Bhd, with registration shown as valid from 15 April 2025 to 14 April 2030. Registration is a regulatory status for a medical device. It is not, by itself, proof that every proposed use is effective or appropriate for every patient.[1]

A TMS coil produces a rapidly changing magnetic field. Because a changing magnetic field can induce an electrical current, the field can stimulate neurons in the underlying cortex without placing an electrode inside the skull. Repeated stimulation can change cortical excitability and influence connected neural networks.[4][5]

The target depends on the clinical protocol. Published EXOMIND studies have commonly targeted the left dorsolateral prefrontal cortex, a region involved in networks supporting executive function, emotional regulation and other higher-order processes. It is better to think of TMS as influencing a targeted part of a connected network rather than as switching a single 'brain centre' on or off.[4][6]

This is also why the word neuromodulation is useful. The goal is not to damage or remove brain tissue. It is to alter neural activity using a controlled physical stimulus.

Before treatment, the clinician should establish the treatment goal and review medical history, medications, neurological history and factors that may increase risk. Screening for implanted electronic or metallic devices and seizure-related risk is particularly important.[5][12]

During treatment, the patient remains awake and is normally seated or reclined. The applicator is positioned over the treatment target, stimulation is adjusted according to the protocol and motor-threshold assessment, and magnetic pulses are delivered in repeated sequences. Patients may notice rhythmic tapping, pulsing or scalp sensations during stimulation. TMS does not require general anaesthesia.[5][7]

The practical details vary with the device and protocol. What should not vary is the clinical principle: an EXOMIND session is a medical neuromodulation procedure, not simply a relaxation or wellness session.

BTL describes EXOMIND sessions as taking under 30 minutes. Published ExoTMS protocols have used treatment periods of about 24.5 minutes. A patient should also allow time for assessment, positioning and clinical review.[2][7]

There is no single EXOMIND schedule that applies to every indication. A 2026 review identified eight ExoTMS studies involving 182 actively treated participants, with protocols using four to six sessions. Individual registered trials have also used four or six sessions at different intervals.[6][8][9][10]

This is different from many conventional depression-TMS protocols, which have historically involved much more frequent treatment over several weeks. A shorter ExoTMS course may reduce treatment burden, but it should not be presented as proof that ExoTMS is universally more effective than conventional TMS. The comparison depends on the indication, protocol and evidence.

Suitability depends on the reason for treatment, the patient's history and the exact protocol. The Malaysian Medical Device Authority's registration for EXOMIND identifies repetitive TMS as the device purpose and includes treatment of major depressive disorder (MDD) in adults who have not achieved satisfactory improvement with prior antidepressant medication, with specified applications involving comorbid anxiety symptoms in MDD, adult OCD and binge-eating disorder. These are regulatory indications, not a statement that every patient with stress, poor sleep, low motivation or 'brain fog' is automatically a candidate.[1]

TMS has a generally favorable safety profile when appropriate screening, stimulation parameters and monitoring are used. Common short-term effects include scalp discomfort, headache, lightheadedness or fatigue. A seizure is a recognized but uncommon risk, and safety guidance emphasizes patient selection, appropriate parameters and trained operators.[5][12][13]

The 2026 ExoTMS review reported that 93.3% of participants described treatment as comfortable and that no serious adverse events were reported across the eight included studies. That is useful information about tolerability, but the evidence base is still relatively small and several studies were sponsor-related. The finding should therefore not be interpreted as proof that serious events are impossible.[6]

Metallic or electronic implants require particular attention because of the magnetic field. Patients should not assume that an implant is safe simply because it is outside the brain. The exact device instructions and safety screening should be checked before treatment.[5]

The evidence becomes clearer when it is separated into layers.

TMS as a treatment class has a large clinical literature, including controlled evidence for major depressive disorder in appropriately selected patients. Professional guidance describes TMS as an established clinical modality for selected indications.[5][13]

ExoTMS is newer. The 2026 peer-reviewed review included eight studies and 182 active-treated participants, with protocols generally using four to six sessions. It found high reported comfort, but the authors also describe a mix of study designs and indications.[6]

Specific ExoTMS studies are also still developing. A 2025 study of binge-eating symptoms reported reductions in symptom scores after six treatments, but the study was sponsored by BTL and involved a specific population. Registered studies have examined mental well-being, sleep and stress, willpower and food cravings, and brain reward pathways. Some of these studies have completed, but trial registration itself is not proof of effectiveness, and results are not necessarily available for every registered study.[7][8][9][10][11]

The practical conclusion is not that EXOMIND is 'unproven'. It is that evidence is indication-specific. A positive result for conventional rTMS in depression should not automatically be transferred to sleep, stress, cravings, focus or general wellness.

Before treatment, I would encourage a patient to ask six questions: What exactly are we treating? What evidence supports this exact use? Am I medically suitable? What is the local regulatory basis? How will response be measured? What happens if it does not help?

A good consultation should identify the treatment goal, explain why TMS is being considered, discuss alternatives where relevant, review safety factors and define how progress will be assessed. If a clinic presents one short course as a universal solution for depression, stress, poor sleep, focus, cravings and general wellness, ask for the evidence and regulatory basis for each claim.

The same principle applies to marketing numbers. A percentage reported in promotional material may describe patient experience, satisfaction or a particular study population. It does not necessarily represent independent comparative efficacy across all patients.

EXOMIND is a BTL system for delivering TMS through ExoTMS technology. Its mechanism is based on electromagnetic induction, and the treatment is non-invasive. Published ExoTMS studies generally use short courses of four to six sessions, but the exact protocol depends on the indication.

The important distinction is between what is established for TMS as a treatment class and what is specifically demonstrated for EXOMIND. TMS has substantial evidence for selected clinical uses, while device-specific and broader wellness applications have a newer and more limited evidence base.

If you are considering EXOMIND, the useful question is not simply 'Does it work?' Ask instead: what problem are we treating, what evidence supports this exact use, am I suitable, how is the treatment regulated locally, and how will we know whether it is helping?